Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $877000.0.

  • Harvard Bioscience's Free Cash Flow rose 15092.92% to $877000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 78047.34%. This contributed to the annual value of -$1.2 million for FY2024, which is 10983.66% down from last year.
  • Per Harvard Bioscience's latest filing, its Free Cash Flow stood at $877000.0 for Q3 2025, which was up 15092.92% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Free Cash Flow ranged from a high of $4.1 million in Q3 2023 and a low of -$2.5 million during Q1 2022
  • Its 5-year average for Free Cash Flow is $877947.4, with a median of $877000.0 in 2025.
  • In the last 5 years, Harvard Bioscience's Free Cash Flow crashed by 37731.38% in 2022 and then soared by 190193.24% in 2023.
  • Over the past 5 years, Harvard Bioscience's Free Cash Flow (Quarter) stood at -$241000.0 in 2021, then soared by 1114.11% to $2.4 million in 2022, then soared by 42.1% to $3.5 million in 2023, then tumbled by 59.0% to $1.4 million in 2024, then plummeted by 38.41% to $877000.0 in 2025.
  • Its Free Cash Flow was $877000.0 in Q3 2025, compared to $2.7 million in Q2 2025 and $2.5 million in Q1 2025.